



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/626,155
Filing Date	July 24, 2003
First Named Inventor	Scott Beers
Group Art Unit	To be Assigned 1626
Examiner Name	To be Assigned G. Shameem
Attorney Docket Number	PRD 0022

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**


Examiner's Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
af		BIEMOND, P. et al., "Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: in vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase." <i>Annals of the Rheumatic Diseases</i> , 1986, pages 249-255.	
		GOULD, P.L. et al., "Salt selection for basic drugs." <i>Intl. J. Pharmaceutics</i> , 1988, pages 201-217.	
		MIESEL, R. et al., "Antiinflammatory Effects of NADPH Oxidase Inhibitors." <i>Inflammation</i> , 1995, pages 347-362, Vol. 19.	
		MIESEL, R. et al., "Suppression of Inflammatory Athritis by Simultaneous Inhibition of Nitric Oxide Synthase and NADPH Oxidase." <i>Free Radical Biology &amp; Medicine</i> , 1996, pages 75-81, Vol. 20, No. 1.	
		HANCOCK, B. C., Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," <i>J. Pharm. Sciences</i> , 1997, pages 1-12, Vol. 86, No. 1.	
		BIANCA, V.D. et al., "β-Amyloid Activates the O Forming NADPH Oxidase In Microglia Monocytes, and Neutrophils." <i>J. Bio. Chem.</i> , 1999, pages 15493-15499, Vol. 274, No. 22.	
		BEGLEY, T.P. et al., "The Biosynthesis of Nicotinamide Adenine Dinucleotides in Bacteria," <i>Vitamins &amp; Hormones</i> , 2001, pages 103-119, Vol. 61.	

Examiner Signature	<i>G. Shameem</i>	Date Considered	9/7/05
-----------------------	-------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

Application Number	To be Assigned
Filing Date	July 24, 2003
First Named Inventor	Scott Beers
Group Art Unit	Not yet assigned 1626
Examiner Name	Not yet assigned G. Sh
Attorney Docket Number	PRD 0022

(use as many sheets as necessary)  
Sheet 1 of 1

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	8/30/05
--------------------	--------------------	-----------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

Examiner Signature		Date Considered	8/30/08
-----------------------	---	--------------------	---------